Cambridge Investment Research Advisors’s ADMA Biologics ADMA Stock Holding History

Cambridge Investment Research Advisors’s Portfolio ADMA Stock Details ADMA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$144K	Buy	17,179 +3,994	+30%	+$36.4K	﹤0.01%	3890
2026 Q1	$119K	Buy	13,185 +620	+5%	+$9.78K	﹤0.01%	3769
2025 Q4	$229K	Buy	+12,565	New	+$212K	﹤0.01%	3461
2024 Q4	–	Sell	-29,293	Closed	-$586K	–	3463
2024 Q3	$586K	Buy	29,293 +2,251	+8%	+$35K	﹤0.01%	2276
2024 Q2	$302K	Buy	+27,042	New	+$227K	﹤0.01%	2699
2024 Q1	–	Sell	-15,000	Closed	-$68K	–	3302
2023 Q4	$68K	Hold	15,000	–	–	﹤0.01%	3077
2023 Q3	$54K	Buy	15,000 +3,572	+31%	+$13.7K	﹤0.01%	3029
2023 Q2	$42K	Sell	11,428 -10,000	-47%	-$37.1K	﹤0.01%	3090
2023 Q1	$71K	Buy	+21,428	New	+$74.1K	﹤0.01%	2997
2019 Q1	–	Sell	-10,000	Closed	-$24K	–	2275
2018 Q4	$24K	Buy	+10,000	New	+$49.5K	﹤0.01%	2115

Other funds holding ADMA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Cambridge Investment Research Advisors's ADMA Position: Q2 2026 in Review

Cambridge Investment Research Advisors increased its ADMA Biologics (ADMA) stake by 30% in Q2 2026, buying an estimated $36.4K and bringing the position to 17,179 shares worth $144K. The position accounts for ﹤0.01% of the portfolio, ranked #3890.

Cambridge Investment Research Advisors first reported a position in ADMA in Q4 2018 and has held it in 10 quarters since. The position peaked at $586K in Q3 2024. 323 funds tracked by Wall St. Rank hold ADMA as of Q2 2026.

Cambridge Investment Research Advisors held 17,179 shares of ADMA Biologics worth $144K as of Q2 2026.
Cambridge Investment Research Advisors bought 3,994 ADMA Biologics shares in Q2 2026, an estimated $36.4K.
ADMA Biologics made up ﹤0.01% of Cambridge Investment Research Advisors's portfolio in Q2 2026, its #3890 holding.
Cambridge Investment Research Advisors first reported a position in ADMA Biologics in Q4 2018 and has held it in 10 quarters since.
Cambridge Investment Research Advisors's ADMA Biologics position peaked at $586K in Q3 2024.
323 funds tracked by Wall St. Rank held ADMA Biologics as of Q2 2026.

Based on Cambridge Investment Research Advisors's 13F filing for Q2 2026, filed 27 Jul 2026.